GlassScriptPhysician profile
Mario A Henriquez
NPI 1629000948
$1,996.09
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2021: $1,546 · 2022: $80.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,105.27 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $454.49 | 2019-2021 | |
| Vifor Pharma, INC. | $112.35 | 2019-2021 | |
| Akebia Therapeutics INC | $58.55 | 2019-2021 | |
| Hologic INC | $55.26 | 2021 | |
| Mallinckrodt Enterprises LLC | $40.38 | 2019 | |
| Novo Nordisk INC | $39.64 | 2019-2022 | |
| Allergan, INC. | $32.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.43 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.26 | 2022 | |
| Alexion Pharmaceuticals, INC. | $25.17 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Henriquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.